

# Scheduled screening versus preventive treatment for the control of malaria in pregnancy in Malawi: a randomized controlled trial

<b>Submission date</b> 14/03/2011	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 07/04/2011	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 30/03/2020	<b>Condition category</b> Infections and Infestations	<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Prof Feiko ter Kuile

**Contact details**  
Liverpool School of Tropical Medicine  
Pembroke Place  
Liverpool  
United Kingdom  
L3 5QA

## Additional identifiers

**Protocol serial number**  
PACTR201103000280319; Prot 10.74 LSTM; P.07/10/955 (COMREC)

## Study information

**Scientific Title**

Scheduled intermittent screening and treatment in pregnancy (ISTp) versus intermittent preventive treatment with sulphadoxine-pyrimethamine (IPTp-SP) in women protected by insecticide treated nets (ITNs) for the control of malaria in pregnancy in Malawi: a randomized controlled trial

## Acronym

ISTp-Malawi

## Study objectives

Scheduled intermittent screening with malaria rapid diagnostic tests (RDTs) and treatment of RDT-positive women with dihydroartemisinin-piperaquine (ISTp-DP) is more effective in prevention malaria associated adverse outcomes in pregnancy than the current strategy of intermittent preventive treatment with sulphadoxine-pyrimethamine (IPTp-SP) in the second and third trimesters among HIV-negative women protected by insecticide-treated bed nets.

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

1. Liverpool School of Tropical Medicine (LSTM) Research Ethics Committee, 28/02/2011, P10.74
2. College of Medicine research Ethics Committee (COMREC), 26/11/2010, ref: P.07/10/955

## Study design

Open-label two-arm multicentre randomised controlled superiority trial

## Primary study design

Interventional

## Study type(s)

Prevention

## Health condition(s) or problem(s) studied

Control of malaria in pregnancy

## Interventions

Participants will receive one of the following two interventions during the second and third trimesters of pregnancy which will be provided at each of three scheduled visits between four and six weeks apart:

1. IPTp-SP Group: Treatment with a three tablets of sulphadoxine-pyrimethamine, each containing sulphadoxine (500 mg) and pyrimethamine (25 mg). This is the standard and only drug for IPTp in Africa.
2. ISTp-DP Group: Screening for malaria using a combined HRP-2/ pLDH (P. falciparum/ pan-malaria) rapid diagnostic test (First Response® Malaria pLDH/HRP2 Combo Test, target antigen pLDH (pan); HRP2; Premier Medical Corporation Ltd, USA), and treatment if RDT-positive with dihydroartemisinin-piperaquine (Sigma Tau). Each tablet will contain 40 mg dihydroartemisinin and 320 mg piperaquine.
3. Treatment will be given for three days, with the daily number of tablets depending on the weight of the woman to the nearest half tablet; dosage being 2 mg/kg/day of dihydroartemisinin and 16 mg/kg/day piperaquine

## **Intervention Type**

Mixed

### **Primary outcome(s)**

1. In women in their first or second pregnancy: composite endpoint of adverse birth outcomes, defined as any of:
  - 1.1. Small for gestational age defined as a binary outcome of <10th percentile of fetal weight for attained gestational age
  - 1.2. Preterm birth (spontaneous birth before 37 weeks gestation)
  - 1.3. Low-birth-weight (birth weight under 2,500 grams)
2. In women in their third to fifth pregnancies: Malaria infection at term and delivery will be the primary endpoint, defined as evidence of current or recent infection assessed at delivery by placental histopathology (active or past infection) or rapid diagnostic tests (RDT) (pLDH or HRP2 positive, any species) or PCR positive (any species)

### **Key secondary outcome(s)**

1. Placental malaria (any species)
  - 1.1. Past infection detected by histopathology
  - 1.2. Active infection detected by:
    - 1.2.1. Histopathology
    - 1.2.2. Microscopy
    - 1.2.3. Rapid diagnostic test
    - 1.2.4. Polymerase chain reaction (PCR)
2. Maternal malaria infection (peripheral blood) at delivery, detected by:
  - 2.1. Microscopy
  - 2.2. RDT
  - 2.3. PCR
3. Peripheral malaria infection during pregnancy detected by:
  - 3.1. Microscopy
  - 3.2. PCR
4. Birth weight
  - 4.1. Mean birth weight (grams)
  - 4.2. Low birth weight (<2,500 grams)
5. Gestational age
  - 5.1. Mean gestational age at birth (grams)
  - 5.2. Pre-term birth (<37 weeks)
6. Small for gestational age
7. Maternal haemoglobin and anaemia at delivery:
  - 7.1. Mean maternal haemoglobin (g/dL)
  - 7.2. Anaemia (Hb  $\leq$  11 g/dL)
  - 7.3. Moderate to severe anaemia (Hb  $\leq$  8g/dL)
8. Maternal haemoglobin and anaemia during third trimester:
  - 8.1. Mean maternal haemoglobin (g/dL)
  - 8.2. Anaemia (Hb  $\leq$  11 g/dL)
  - 8.3. Moderate to severe anaemia (Hb  $\leq$  8g/dL)
9. Miscarriage (loss of foetus before 28 weeks gestation)
10. Stillbirth (birth at 28 weeks or later showing no signs of life)
11. Composite endpoint of the primary endpoint plus fetal loss (miscarriage or stillbirths)
12. Infant death
13. Perinatal death (stillbirth or death within 7 days of birth)
14. Neonatal death (death within 28 days of birth)

15. Malaria infection of the newborn, detected by analysis of umbilical cord blood with:
  - 15.1. RDT
  - 15.2. Microscopy
  - 15.3. PCR
16. Foetal haemoglobin and anaemia by sampling of umbilical cord blood at birth:
  - 16.1. Mean foetal haemoglobin (g/dL)
  - 16.2. Foetal anaemia ( $Hb \leq 12.5$  g/dL)
  - 16.3. Moderate to severe foetal anaemia
17. Incidence of documented clinical malaria episodes during the second and third trimesters of pregnancy (history of fever in last 24 hours and documented malaria microscopy or RDT positive)
18. Presence of any evidence of malaria infection at term (last antenatal visit), identified through microscopy or PCR, or at delivery, identified through peripheral and placental RDT, microscopy or PCR, or placental histopathology (active or past infection).
19. Incidence of other illness episodes apparent at scheduled antenatal clinic visits or resulting in unscheduled clinic visits
20. Incidence and prevalence of clinical malaria in infants by seven days and six to eight weeks determined by:
  - 20.1. RDT
  - 20.2. Microscopy
  - 20.3. PCR
21. Prevalence of symptomatic infant anaemia at seven days and six to eight weeks:
  - 21.1. Anaemia
  - 21.2. Moderate to severe anaemia
22. Incidence of other illness episodes in the infants, apparent at scheduled postnatal clinic visits or resulting in unscheduled postnatal clinic visits
23. Safety outcomes:
  - 23.1. Severe cutaneous skin reaction in the mothers within 30 days of drug intake
  - 23.2. Other serious adverse events in the mothers
  - 23.3. Congenital malformations identified by six weeks after birth
  - 23.4. Neonatal jaundice within 24 hours and at seven days
  - 23.5. Laboratory test results outside of normal range
24. Tolerability outcomes:
  - 24.1. Non-serious adverse events in the mothers
  - 24.2. Adherence to study medication
25. Immunology outcomes:
  - 25.1. Concentration of antibodies known to be associated with protection against malaria in pregnancy and in general, including antibodies recognizing variant surface antigens on *P. falciparum* infected erythrocytes that block parasite adhesion to chondroitin sulphate A.
26. Economic outcomes (sub-study):
  - 26.1. The economics sub study will be conducted alongside the main clinical trial. Health facility and exit surveys will be carried out to estimate the costs of the intervention to the health services and households respectively. To capture costs incurred during the first six to eight weeks after delivery, including the costs of caring for low birth weight babies, questions about use of health services will be integrated into the clinical health assessment at six weeks.
  - 26.2. Costs of the two intervention arms to the health facility and household up to six to eight weeks after delivery. Household data will be collected by questionnaire at the six-week clinic visit; health facility data directly from the health facility
  - 26.3. Cost-effectiveness of ISTp-DP versus IPTp-SP measured in terms of cost per each of the following endpoints averted, which are measured in the main trial:
  - 26.4. Adverse birth outcome (still birth, preterm birth or low birth weight)
  - 26.5. Active and past malaria infection of the placenta (detected by histopathology, microscopy or RDT)

26.6. Maternal anaemia

26.7. Peripheral malaria at delivery

26.8. Neonatal deaths

26.9. Cost per disability adjusted life year (DALY) averted will be estimated using the cost data collected and effectiveness data generated by the trial, with necessary adjustments made to the DALY to accommodate outcomes in pregnant women and their newborns

The household and facility data from the cost and cost-effectiveness analysis will be used (alongside data from other studies) to populate a model of the economic burden of malaria in pregnancy.

27. Model the long-term costs and consequences of malaria in pregnancy to the household and health facility in both trial arms

28. Model the costs of scaling up the intervention at regional/national level and investigate affordability in Malawi

29. Acceptability, feasibility, implementability and scale up outcomes

29.1. The overall aim of this sub study is to explore the acceptability, feasibility, implementability and potential for scale-up of ISTp-DP

29.2. Social, cultural and economic determinants of demand, access and use for malaria in pregnancy interventions

29.3. Acceptability of ISTp for provider and user

29.4. Preferences for malaria in pregnancy interventions at the user and provider level

29.5. Factors at facility and district levels which influence the delivery of malaria in pregnancy interventions and in particular the feasibility and implementability of ISTp in the context of other reproductive health interventions (e.g. prevention of mother to child transmission)

29.5. Major barriers to the scale-up and use of interventions to control malaria in pregnancy, specifically of ISTp

### **Completion date**

01/11/2013

## **Eligibility**

### **Key inclusion criteria**

1. Viable singleton pregnancy
2. Gestational age 16 to 28 weeks (inclusive) by LMP (if available) or fundal height
3. No history of IPTp use during this pregnancy
4. Willing to participate and complete the study schedule
5. Has provided written informed consent
6. Resident of study area and intending to stay in the area for the duration of the follow-up
7. Willing to deliver in the labour ward of the study clinic or hospital

### **Participant type(s)**

Patient

### **Healthy volunteers allowed**

No

### **Age group**

Adult

### **Sex**

Female

**Total final enrolment**

1873

**Key exclusion criteria**

1. HIV positive or unknown HIV status
2. Multiple gestations
3. High risk pregnancy resulting in referral to tertiary delivery facilities according to local guidelines
4. Severe anaemia requiring blood transfusion ( $Hb \leq 7.0$  g/dL) at enrolment
5. Known allergy or previous adverse reaction to any of the study drugs
6. Unable to give informed consent (for example due to mental disability)
7. Previous inclusion in the same study

**Date of first enrolment**

01/05/2011

**Date of final enrolment**

01/11/2013

**Locations****Countries of recruitment**

United Kingdom

England

Malawi

**Study participating centre**

Liverpool School of Tropical Medicine

Liverpool

United Kingdom

L3 5QA

**Sponsor information****Organisation**

Liverpool School of Tropical Medicine (UK)

**ROR**

<https://ror.org/03svjbs84>

**Funder(s)**

**Funder type**

Government

**Funder Name**

European and Developing Countries Clinical Trial Partnership (EDCTP)

## Results and Publications

**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration

**Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	13/09/2016		Yes	No
<a href="#">Results article</a>	nested study results	27/05/2019	29/05/2019	Yes	No
<a href="#">Results article</a>	results	23/07/2020	30/03/2020	Yes	No